Metabolic

Featured Article

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Although many of the newer antidiabetic drugs have demonstrated favorable outcomes in clinical trials, some have also been associated with increased risk of adverse CV outcomes.

Latest Features

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Although many of the newer antidiabetic drugs have demonstrated favorable outcomes in clinical trials, some have also been associated with increased risk of adverse CV outcomes.

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Physical Activity for Diabetes: ADA Updated Guidelines

Physical Activity for Diabetes: ADA Updated Guidelines

Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.

Hope for Heart Failure in Thyroid Hormone Therapy

Hope for Heart Failure in Thyroid Hormone Therapy

Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.

Latest News

Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers

Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers

Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.

Canagliflozin Reduces CV Death and Hospitalizations for Heart Failure in T2D

Canagliflozin Reduces CV Death and Hospitalizations for Heart Failure in T2D

Patients with type 2 diabetes at risk for heart failure are particularly likely to benefit from treatment with canagliflozin.

ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes

ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes

The American Diabetes Association has updated its Clinical Standards of Medical Care guidelines for identifying and managing cardiovascular risk factors in diabetes.

Add-On Antihypertensives Compared in Patients With Diabetes on ACEIs, ARBs

Add-On Antihypertensives Compared in Patients With Diabetes on ACEIs, ARBs

The composite significant kidney event end point was defined as the first occurrence of ≥30% decline in eGFR to an eGFR <60mL/min/1.73m2, initiation of dialysis or kidney transplant.

HbA1c Levels Affect Serum Phospholipids, Inflammation in T2D, CVD

HbA1c Levels Affect Serum Phospholipids, Inflammation in T2D, CVD

Investigators sought to determine the association between serum phospholipid fatty acid composition, low-grade inflammation, and glycemic control in patients with T2D.

Low Sperm Count Associated With Worse Metabolic, Cardiovascular, and Bone Health

Low Sperm Count Associated With Worse Metabolic, Cardiovascular, and Bone Health

Researchers tested whether semen quality and reproductive function could be a marker of general health in men.

ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes

ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes

ACP responds to criticism from the ADA, the Endocrine Society, the AACE, and the AADE of guidance that clinicians should aim to achieve an HbA1c level between 7% and 8% in most people with type 2 diabetes.

Tresiba Label Updated With Data on Cardiovascular Outcomes

Tresiba Label Updated With Data on Cardiovascular Outcomes

The FDA has approved an update to the prescribing information for Tresiba to include cardiovascular outcomes and severe hypoglycemia study data.

T2D and Hypertriglyceridemia: No Cardiovascular Benefit With Fenofibrate or Statins

T2D and Hypertriglyceridemia: No Cardiovascular Benefit With Fenofibrate or Statins

Statins were associated with a reduction in mortality but there was no significant difference in the composite end point with fenofibrates alone or in combination with statins.

Reducing Total Daily Insulin Dose in T2D: 3-Meal vs 6-Meal Diet

Reducing Total Daily Insulin Dose in T2D: 3-Meal vs 6-Meal Diet

In people with obesity and type 2 diabetes, a meal schedule that includes a high-energy breakfast promotes weight loss, improves diabetes, and decreases the need for insulin.

Sign Up for Free e-Newsletters